Sunday, June 26, 2022

The Attractiveness of Investing In Regulus Therapeutics Inc. (RGLS) is Growing

In a filing, Regulus Therapeutics Inc. revealed its Chief Scientific Officer Drygin Denis acquired Company’s shares for reported $5362.0 on Feb 04. In the deal valued at $0.23 per share,23,314 shares were bought. As a result of this transaction, Drygin Denis now holds 23,314 shares worth roughly $ 6527.920000000001.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Then, Hagan Joseph P bought 100,000 shares, generating $21,520 in total proceeds. Upon buying the shares at $0.22, the President and CEO now owns 417,006 shares.

Taking this into account, B. Riley FBR Inc. initiated its Regulus Therapeutics Inc. [RGLS] rating to a Neutral in a research note published on Tuesday, March 28, 2018; the price target was $1. PT values the company’s stock at a premium of 72.0 to its Tuesday closing price. A number of analysts have revised their coverage, including Leerink Partners’s analysts, who began to cover the stock in early January with a ‘”an Outperform”‘ rating. Chardan Capital Markets also remained covering RGLS and reiterated its “Buy” recommendation on June 13, 2017. Wedbush maintained its rating on March 06, 2017. It rated RGLS as “an Outperform”.

Price Performance Review of RGLS

On Tuesday, Regulus Therapeutics Inc. [NASDAQ:RGLS] saw its stock fall -1.97% to $0.28. On the same session, the stock had its day’s lowest price of $0.2725, but rose to a high of $0.30. Over the last five days, the stock has gained 10.80%. Regulus Therapeutics Inc. shares have fallen nearly -9.75% since the year began. Nevertheless, the stocks have fallen -71.42% over the past one year. While a 52-week high of $1.05 was reached on 04/04/22, a 52-week low of $0.16 was recorded on 05/09/22. SMA at 50 days reached $0.2369, while 200 days put it at $0.3612. A total of 2.58 million shares were traded, compared to the trading of 0.72 million shares in the previous session.

Levels Of Support And Resistance For RGLS Stock

The 24-hour chart illustrates a support level at 0.2712, which if violated will result in even more drops to 0.2581. On the upside, there is a resistance level at 0.2987. A further resistance level may holdings at 0.3131. The Relative Strength Index (RSI) on the 14-day chart is 57.81, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.0088, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 29.34%. Stochastics %K at 69.68% indicates the stock is a holding.

Regulus Therapeutics Inc. [RGLS] – Who Are The Largest Shareholders?

Additionally, DAFNA Capital Management LLC decreased 0.00% of its stake after which the total value it holdings stand at $1,594,444, while The Vanguard Group, Inc. added 21.61% of its stake to hold $1.05 million in the firm. Over the last quarter, Asymmetry Capital Management LP purchased 1,329,553 shares of Regulus Therapeutics Inc., while Victory Capital Management, Inc. bought -513 shares. At present, Sarissa Capital Management LP is holding 1,851,851 shares valued at $0.53 million. Ikarian Capital LLC owned 1,289,130 shares of the company at the time of its most recent 13F filing, worth $0.37 million.

However, 3 analysts have rated RGLS stock as an Overweight in their predictions for 2022.

Latest news

Related news


Please enter your comment!
Please enter your name here




Download Free eBook For

The 5 Best Growth Stocks 2022

100% free. stop anytime no spam